Drug Profile
Unesbulin - PTC Therapeutics
Alternative Names: PTC-596Latest Information Update: 28 Feb 2024
Price :
$50
*
At a glance
- Originator PTC Therapeutics
- Developer PTC Therapeutics; University of Oklahoma
- Class Amines; Antineoplastics; Benzimidazoles; Fluorinated hydrocarbons; Pyrimidines; Small molecules
- Mechanism of Action BMI1 protein inhibitors; Tubulin polymerisation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II/III Leiomyosarcoma
- No development reported Diffuse intrinsic pontine glioma; Fallopian tube cancer; Glioblastoma; Ovarian cancer; Peritoneal cancer; Solid tumours
Most Recent Events
- 28 Feb 2024 No recent reports of development identified for phase-I development in Diffuse intrinsic pontine glioma(In adolescents, In children, Newly diagnosed, In adults) in USA (PO, Capsule)
- 28 Feb 2024 No recent reports of development identified for phase-I development in Glioblastoma(In adolescents, In children, Newly diagnosed, In adults) in USA (PO, Capsule)
- 20 Oct 2023 Pharmacokinetics data from a phase Ib trial in Leiomyosarcoma presented at the 48th European Society for Medical Oncology Congress (ESMO-2023)